Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Reduced Dose of Cabergoline for Lactation Inhibition After Second-Trimester Abortion or Pregnancy Loss
Sponsor: Stanford University
Summary
Most patients seeking abortion care or management of pregnancy loss in the second trimester will lactate, which can be physically and emotionally painful. The efficacy of a one-time dose of cabergoline has been previously demonstrated to prevent breast symptoms for these patients. This study seeks to determine if investigators can more precisely manage these patients with a reduced dose appropriate for the physiology of the second trimester, thereby reducing the medication cost and reducing or eliminating the uncomfortable medication side effects.
Key Details
Gender
FEMALE
Age Range
18 Years - 55 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2026-07
Completion Date
2027-07
Last Updated
2025-12-12
Healthy Volunteers
No
Conditions
Interventions
Cabergoline
Cabergoline